Germany-based Boehringer Ingelheim and United States-based Eli Lilly and Company (NYSE:LLY) announced on Wednesday that the United States Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) assessing a potential new indication to reduce blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes.
The company has submitted the sNDA based on the outcome from the DINAMO phase III trial, in which Jardiance was associated with a statistically significant decrease in the primary endpoint of change from baseline in A1c (a marker of average blood sugar) at 26 weeks compared with placebo in participants aged 10-17 years with type 2 diabetes.
Mohamed Eid, MD, MPH, MHA., vice president, Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc, said, 'There are clear unmet needs for young people living with type 2 diabetes, which has nearly doubled in prevalence in people aged 10-19 over the past two decades. We look forward to working closely with the FDA during the review process and while we await a decision on our efforts to bring another potential treatment option to children 10 years and older with type 2 diabetes.'
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy